IRMD Iradimed Corp

IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference

IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference

WINTER SPRINGS, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi, the Company's President and Chief Executive Officer, will present at the 36th Annual Roth Conference in Laguna Niguel, CA. Mr. Susi is scheduled for a live fireside chat on Tuesday, March 19, at 12:30 p.m. PT.

A live webcast and a replay of the fireside chat will be available on Iradimed’s Investor page at .

This year’s event will consist of 1-on-1 / small group meetings, analyst-selected fireside chats, thematic and industry panels, and company presentations by executive management from approximately 500 private and public companies in various growth sectors.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.

We are the only provider of a non-magnetic intravenous (“IV”) infusion pump system designed to be safe during MRI procedures. We were the first to develop an infusion delivery system that eliminates many dangers and problems during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI-compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other unique features to deliver anesthesia safely and predictably and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.

Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other unique features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The IRADIMED 3880 has a compact, lightweight design, allowing it to travel with the patient from the critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the IRADIMED 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The IRADIMED 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and effectively communicates patient vital signs information to clinicians.

For more information, please visit .



Media Contact:
John Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
 
EN
13/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Iradimed Corp

 PRESS RELEASE

IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results...

IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share Reports record revenue of $17.6 million for the first quarter of 2024.Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the first quarter of 2024.Reports first quarter of 2024 operating income of $4.7 million, an increase of 18.5 percent compared to the same period in 2023.Declares a regular quarterly cash dividend of $0.15 per common share for the second quarter of 2024, payable May 30, 2024. WINTER SPRINGS, Fla., May ...

 PRESS RELEASE

IRADIMED CORPORATION to Hold 2024 First Quarter Financial Results Conf...

IRADIMED CORPORATION to Hold 2024 First Quarter Financial Results Conference Call on May 2nd WINTER SPRINGS, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 first quarter financial results before the market opens on Thursday, May 2, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, . Once registered, a dial-i...

 PRESS RELEASE

IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference

IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference WINTER SPRINGS, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi, the Company's President and Chief Executive Officer, will present at the 36th Annual Roth Conference in Laguna Niguel, CA. Mr. Susi is scheduled for a live fireside chat on Tuesday, March 19, at 12:30 p.m. PT. A live webcast and a replay of the fireside chat will be available on Iradimed’s Investor page at . This year’s event will consist of 1-on-1 / small group meetings, analy...

 PRESS RELEASE

IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of...

IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023. Reports GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.39 for the fourth quarter of 2023. Reports GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.48 for the full year of 2023. Reports fourth quarter of 2023 operating income of $5.2 million, an increase of 21.3%, compared to the same period in 2022 and full-year operating income of $20.0 million, an increase of 28.2%, com...

 PRESS RELEASE

IRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Con...

IRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th. WINTER SPRINGS, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 fourth quarter financial results before the market opens on Thursday, February 8, 2024. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, .Once registered, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch